Pitavastatin

Pitavastatin is a statin, a medicine taken by mouth to lower LDL cholesterol. The FDA label says it is indicated to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia. Livalo is the brand name on the label read.

Also called Livalo

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 861634; UNII IYD54XEG3W. The label names the substance as pitavastatin calcium, so UNII IYD54XEG3W is the UNII of the salt form and is a broad match. MeSH lists this substance under entry terms and not as its own descriptor, so no MeSH identifier is recorded. Class: HMG-CoA Reductase Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Kowa Pharmaceuticals America, Inc. label for LIVALO (pitavastatin calcium), application NDA022363, effective 2026-03-31 in openFDA. This page records the label indication and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 8 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
8
Phase 3 or 4
8
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedUnknown statusAll statuses
Phase 3213
Phase 4325
All phases538

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 3 more.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII IYD54XEG3W

Claims and evidence

Context People for whom the US label of pitavastatin lists an indication: adults with primary hyperlipidemia

Recipient
Adult
Population
Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol (LDL cholesterol) indication.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults, as the passage read states
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Adults with primary hyperlipidemia
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of LIVALO (pitavastatin calcium), in the Kowa Pharmaceuticals America, Inc. version dated 2026-03-31 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.

    Applies to Adult People for whom the US label of pitavastatin lists an indication: adults with primary hyperlipidemia

    Certainty method
    Not assessed
    Limitations
    This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-07
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for LIVALO (pitavastatin calcium), Kowa Pharmaceuticals America, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 44dcbf97-99ec-427c-ba50-207e0069d6d2 (manufacturer Kowa Pharmaceuticals America, Inc., application NDA022363), returned on 2026-11-07. The label text is dated 2026-03-31 (effective_time). Other openFDA records of pitavastatin labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that gives the LDL-cholesterol indication.
      Retrieved
      Source effective date
      2026-03-31
      Source state
      Current
      Version fingerprint
      57ec858494fdaae2ff3f5e8c1545ff2fc4750120c8b1dca254bd489647b97ee9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-07, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for LIVALO (pitavastatin calcium), Kowa Pharmaceuticals America, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 44dcbf97-99ec-427c-ba50-207e0069d6d2 (manufacturer Kowa Pharmaceuticals America, Inc., application NDA022363), returned on 2026-11-07. The label text is dated 2026-03-31 (effective_time). Other openFDA records of pitavastatin labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260331.
      Retrieved
      Source effective date
      2026-03-31
      Source state
      Current
      Version fingerprint
      57ec858494fdaae2ff3f5e8c1545ff2fc4750120c8b1dca254bd489647b97ee9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-07, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry trials 8

Record details

Record id
cardio:pitavastatin
Content hash
0897bc53b0f65411a4f021549d892d6abd83796be4c2b65767d410c691a10bb6